natgillin/translations-raw huggingface dataset:
The prodrug of claim 6, wherein the backbone moieties comprise a branching core of the following formula: wherein the dashed line indicates attachment to the remainder of the backbone moiety. 
Predlijek prema zahtjevu 6, naznačen time što dijelovi okosnice sadrže granajuću jezgru slijedeće formule: pri čemu isprekidana crta označava vezanje na ostatak dijela okosnice.
L2* is a spacer connected to L* and comprising a chemical functional group intended for conjugation to a hydrogel; 
* je razmaknica spojena s L* i obuhvaća kemijsku funkcionalnu skupinu namijenjenu za konjugaciju na hidrogel;
wherein exendin is an exendin agonist, an exendin analogue, a truncated exendin, a truncated exendin agonist, a truncated exendin analogue, an extended exendin, an extended exendin agonist, an extended exendin analogue, GLP-1, a GLP-1 analogue, such as GLP-1 or GLP-1 analogue in amidated, truncated or extended form; and wherein the chemical functional group is selected from carboxylic acid and activated derivatives, amino, maleimide, thiol and derivatives, sulfonic acid and derivatives, carbonate and derivatives, carbamate and derivatives, hydroxyl, aldehyde, ketone, hydrazine, isocyanate, isothiocyanate, phosphoric acid and derivatives, phosphonic acid and derivatives, haloacetyl, alkyl halides, acryloyl and other alpha-beta unsaturated michael acceptors, arylating agents like aryl fluorides, hydroxylamine, disulfides like pyridyl disulfide, vinyl sulfone, vinyl ketone, diazoalkanes, diazoacetyl compounds, oxirane, and aziridine. 
pri čemu eksendin je agonist eksendina, analog eksendina, skraćeni eksendin, skraćeni agonist eksendina, skraćeni analog eksendina, prošireni eksendin, prošireni agonist eksendina, prošireni analog eksendina, GLP-1, analog GLP-1, kao što je GLP-1 ili analog GLP-1 u amidiranom, skraćenom ili proširenom obliku; i pri čemu je kemijska funkcionalna skupina odabrana od karboksilne kiseline i aktiviranih derivata, amino, maleimida, tiola i derivata, sulfonske kiseline i derivata, karbonata i derivata, karbamata i derivata, hidroksila, aldehida, ketona, hidrazina, izocijanata, izotiocijanata, fosforne kiseline i derivata, fosfonske kiseline i derivata, haloacetila, alkil halogenida, akriloil i drugih alfa-beta nezasićenih Michaelovih akceptora, arilacijskih sredstava poput aril fluorida, hidroksilamina, disulfida kao piridil disulfida, vinil sulfona, vinil ketona, diazoalkana, spojeva diazoacetila, oksirana i aziridina.
D represents an exendin and wherein exendin is an exendin agonist, an exendin analogue, a truncated exendin, a truncated exendin agonist, a truncated exendin analogue, an extended exendin, an extended exendin agonist, an extended exendin analogue, GLP-1, a GLP-1 analogue, such as GLP-1 or GLP-1 analogue in amidated, truncated or extended form. 
D predstavlja eksendin i pri čemu eksendin je agonist eksendina, analog eksendina, skraćeni eksendin, skraćeni agonist eksendina, skraćeni analog eksendina, prošireni eksendin, prošireni agonist eksendina, prošireni analog eksendina, GLP-1, analog GLP-1, kao što je GLP-1 ili analog GLP-1 u amidiranom, skraćenom ili proširenom obliku.
A humanized antibody or antigen binding fragment thereof capable of specific binding to clusterin, wherein the humanized antibody or antigen binding fragment thereof comprises a light chain variable region as set forth in SEQ ID NO. 
Humanizirano protutijelo ili njegov ulomak koji veže antigen sposoban za specifično vezanje za klusterin, naznačeno time što humanizirano protutijelo ili njegov ulomak koji veže antigen sadrži varijabilnu regiju lakog lanca kako je prikazano u SEQ ID NO.
The humanized antibody of claim 1, wherein the antibody or an antigen binding fragment thereof comprises a light chain as set forth in SEQ ID NO. 
Humanizirano protutijelo prema patentnom zahtjevu 1, naznačeno time što protutijelo ili njegov ulomak koji veže antigen sadrži laki lanac kako je prikazano u SEQ ID NO.
An isolated nucleic acid selected from the group consisting of: 
Izolirana nukleinska kiselina naznačena time što je odabrana iz skupine koju čine:
An isolated nucleic acid encoding the light chain and the heavy chain of the humanized antibody of claim 2. 
b izoliranu nukleinsku kiselinu koja kodira laki lanac i teški lanac humaniziranog protutijela prema zahtjevu 2.
A pharmaceutical composition comprising the humanized antibody or antigen binding fragment thereof of claim 1 or the humanized antibody of claim 2, and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak naznačen time što sadrži humanizirano protutijelo ili njegov ulomak koji veže antigen prema zahtjevu 1 ili humanizirano protutijelo prema zahtjevu 2, i farmaceutski prihvatljiv nosač.
contacting said lactose-free sample with an assay medium which comprises a microorganism, a gelling agent and an indicator capable of detecting growth or inhibition of the microorganism to obtain an assembly of the lactose-free sample and the assay medium; 
dovođenje u kontakt navedenog uzorka bez laktoze s medijem za ispitivanje koji sadrži mikroorganizam, sredstvo za geliranje i indikator koji može detektirati rast ili inhibiciju mikroorganizma da se dobije skup uzorka bez laktoze i medija za ispitivanje;
incubating the assembly obtained in step (a) for a period of time sufficient to grow the microorganism in case no antibiotic is present in said lactose-free sample; and 
inkubiranje skupa dobivenog u koraku (a) tijekom vremenskog perioda dovoljnog za uzgoj mikroorganizma u slučaju da u navedenom uzorku bez laktoze nema antibiotika; i
a known amount of an antibiotic is added in step (a), or 
poznata količina antibiotika dodaje se u koraku (a), ili
contacting each dilution obtained in step (a) with an assay medium comprising a microorganism, a nutrient and an indicator capable of detecting growth or inhibition of the microorganism to obtain a mixture; 
dovođenje u kontakt svakog razrjeđenja dobivenog u koraku (a) s medijem za ispitivanje koji sadrži mikroorganizam, hranjivu tvar i indikator koji može detektirati rast ili inhibiciju mikroorganizma da se dobije smjesa;
incubating each mixture obtained in step (b) for a period of time sufficient to grow the microorganism in case no antibiotic is present in the sample; 
inkubiranje svake smjese dobivene u koraku (b) tijekom vremenskog perioda dovoljnog za uzgoj mikroorganizma u slučaju da u uzorku nema antibiotika;
a container with assay medium which comprises a microorganism, a gelling agent and an indicator capable of detecting growth or inhibition of the microorganism to obtain a mixture; 
spremnik s medijem za ispitivanje koji sadrži mikroorganizam, sredstvo za geliranje i indikator koji može detektirati rast ili inhibiciju mikroorganizma da se dobije smjesa;
a container comprising powdered milk. 
spremnik koji sadrži mlijeko u prahu.
A composition comprising a lactose-free sample containing less than 0.01% w/w lactose, a microorganism, a gelling agent, an indicator and one of milk and milkpowder, wherein said lactose free sample is selected from samples from industrial waste streams from plants, including both aqueous and solid waste streams, samples from effluents and surface waters and samples from veterinary urine or manure. 
Pripravak koji sadrži uzorak bez laktoze koji sadrži manje od 0.01% m/m laktoze, mikroorganizam, sredstvo za geliranje, indikator i jedno od mlijeka i mlijeka u prahu, naznačen time što je navedeni uzorak bez laktoze odabran iz uzoraka iz industrijskog otpada od biljaka, uključujući vodene i krute otpadne struje, uzorke iz efluenata i površinskih voda i uzorke iz veterinarskog urina ili stajskog gnoja.
A composition comprising a bacterial strain of the genus Blautia, for use in a method of treating or preventing visceral hypersensitivity. 
Sastav koja obuhvaća bakterijski soj vrste Blautia hydrogenotrophica, za upotrebu u postupku liječenja ili prevenciji visceralne hipersenzitivnosti.
The composition of claim 1, wherein the visceral hypersensitivity is associated with IBS, Crohn's disease, ulcerative colitis, functional dyspepsia or infantile colic. 
Sastav za upotrebu prema zahtjevu 1, gdje je visceralna hipersenzitivnost povezana sa IBS-om, Chronovom bolesti, ulceroznim kolitisom, funkcionalnom dispepsijom ili dojenačkim kolikama.
The composition of claim 2, wherein the visceral hypersensitivity is associated with IBS, Crohn's disease, ulcerative colitis or functional dyspepsia. 
Sastav za upotrebu prema zahtjevu 2, gdje je visceralna hipersenzitivnost povezana sa IBS-om, Chronovom bolesti, ulceroznim kolitisom ili funkcionalnom dispepsijom.
The composition of any preceding claim, wherein the composition is for use in: 
Sastav za upotrebu prema bilo kojem prethodnom zahtjevu, gdje je sastav za upotrebu u:
a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA sequence of a bacterial strain of Blautia stercoris; or 
Sastav za upotrebu prema zahtjevima 1-6, gdje bakterijski soj ima 16s rRNK sekvencu koja je najmanje 95%, 96%, 97%, 98%, 99%, 99.5% ili 99.9% identična sa 16s rRNK sekvencom bakterijskog soja Blautia hydrogenotrophica.
a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA sequence of a bacterial strain of Blautia wexlerae. 
Sastav za upotrebu prema zahtjevu 7, gdje bakterijski soj ima 16s rRNK sekvencu koja je najmanje 97%, 98%, 99%, 99.5% ili 99.9% identična sa SEQ ID NO:5 ili koja ima 16s rRNK sekvencu SEQ ID NO:5.
The composition of claim 1, wherein the composition comprises a bacterial strain of the species Blautia hydrogenotrophica, Blautia stercoris or Blautia wexlerae for use in reducing colonisation of the gastrointestinal tract by sulphate reducing bacteria (SRB), lowering H2S levels or preventing elevated H2S levels in the gastrointestinal tract in the treatment or prevention of visceral hypersensitivity. 
smanjenju kolonizacije gastrointestinalnog trakta upotrebom bakterija koje reduciraju sulfate (SRB), snižavanjem H2S razina ili prevenciji povećanja H2S razina u gastrointestinalnom traktu u liječenju ili prevenciji visceralne hipersenzitivnosti. Sastav za upotrebu prema bilo kojem prethodnom zahtjevu, gdje je sastav za oralnu primjenu.
An antibody polypeptide according to Claim 1 comprising or consisting of an intact antibody or an antigen-binding fragment selected from the group consisting of Fv fragments, Fab-like fragments and domain antibodies. 
Polipeptid antitijela prema Zahtjevu 1, koji sadrži ili se sastoji od intaktnog antitijela ili fragmenta za vezanje antigena koji je izabran iz grupe koja se sastoji od Fv fragmenata i fragmenata sličnih Fab.
a replacement at the endogenous mouse k immunoglobulin light chain variable region locus of endogenous mouse k immunoglobulin light chain variable region gene segments with a single rearranged human Vk1-39/Jk gene segment or a single rearranged human Vk3-20/Jx gene segment, wherein the human gene segment is operably linked to an endogenous mouse k constant gene and wherein the mouse lacks an endogenous mouse k immunoglobulin light chain variable region locus that is capable of rearranging and forming a gene that encodes a mouse k variable region; and, 
zamjenu endogenog mišjeg lokusa varijabilne regije imunoglobulinskog lakog lanca k svih segmenata gena endogene mišje varijabilne regije imunoglobulinskog lakog lanca k s preuređenim humanim segmentom gena Vk1-39/J, preuređenim humanim segmentom gena Vk3-20/J ili njihovom kombinacijom, pri čemu je preuređeni humani segment gena operativno povezan s endogenim mišjim konstantnim genom k, pri čemu miš nema endogeni mišji lokus varijabilne regije imunoglobulinskog lakog lanca k koji je sposoban za preuređivanje i formiranje gena koji šifrira mišju varijabilnu regiju k; i
the mouse further comprises a mouse k intronic enhancer 5' with respect to the mouse light chain constant region; or 
miš dodatno sadrži mišji k intronski pojačivač 5' u odnosu na mišju konstantnu regiju lakog lanca; ili
control condition 1, after a charging power source is connected to the universal rechargeable battery, the lithium-ion battery charging/discharging control circuit performs a charging status upon detection of the charging voltage connection, and during the charging status, the lithium-ion battery charging/discharging control circuit cutoffs the regulated discharge voltage output and performs charging of the lithium-ion battery; 
kontrolni uvjet 1, nakon što je izvor punjenja povezan na univerzalnu punjivu bateriju, kontrolni krug za punjenje/pražnjenje litij-ionske baterije obavlja status punjenja nakon detekcije priključka napona punjenja, i tijekom statusa punjenja, kontrolni krug za punjenje/pražnjenje litij-ionske baterije prekida regulirani naponski izlaz pražnjenja i obavlja punjenje litij-ionske baterije;
control condition 3, when the charging power source is disconnected from the universal rechargeable battery, the lithium-ion battery charging/discharging control circuit detects the disconnection of the charging power source, and discharges remaining power stored in a filter capacitor during the charging, such that a voltage across a positive electrode and a negative electrode of the universal rechargeable battery drops rapidly to be equal to or lower than a maximum open circuit voltage and a discharging status is performed, and during the discharging status, the lithium-ion battery charging/discharging control circuit cutoffs a charging output and performs a regulated voltage discharge, and performs a regulated voltage output according to control condition 4; 
kontrolni uvjet 3, kada je izvor punjenja isključen iz univerzalne punjive baterije, kontrolni krug za punjenje/pražnjenje litij-ionske baterije detektira isključenje izvora punjenja, i prazni preostalu snagu koja se nalazi u filter kondenzatoru tijekom punjenja, tako da napon na pozitivnoj elektrodi i negativnoj elektrodi univerzalne punjive baterije brzo pada kako bi bio jednak ili niži nego maksimalni napon otvorenog kruga i status pražnjenja je izvršen, a tijekom statusa pražnjenja, kontrolni krug za punjenje/pražnjenje litij-ionske baterije prekida punjenje i obavlja regulirano naponsko pražnjenje, i obavlja regulirani naponski izlaz prema kontrolnom uvjetu 4, gdje maksimalni napon otvorenog kruga je u opsegu od 1.5V do 1.725V;
control condition 7, during the discharging of the universal rechargeable battery, the lithium-ion battery charging/discharging control circuit detects the temperature of the lithium-ion battery, and cutoffs the regulated voltage output when the temperature of the lithium-ion battery raises to a discharging upper threshold temperature TDH and restores the regulated voltage output when the temperature of the lithium-ion battery decreases to be lower than TDH-ΔT2, wherein TDH is a preset discharging upper threshold temperature of the lithium-ion battery, and ΔT2 is a preset backlash temperature corresponding to a backlash voltage of the TDH detection threshold; 
kontrolni uvjet 7, tijekom pražnjenja univerzalne punjive baterije, kontrolni krug za punjenje/pražnjenje litij-ionske baterije detektira temperaturu litij-ionske baterije, i prekida regulirani naponski izlaz kada temperatura litij-ionske baterije raste do gornjeg praga temperature TDH pražnjenja i uspostavlja regulirani naponski izlaz kada se temperatura litij-ionske baterije smanji kako bi bila niža nego TDH-ΔT2, gdje TDH je unaprijed podešeni gornji prag temperature pražnjenja litij-ionske baterije, a ΔT2 je unaprijed podešena temperatura mrtve zone koja odgovara naponu mrtve zone TDH praga za detekciju;
vii) capable of releasing one or more neurotrophic factors; 
sposobna za oslobađanje jednog ili više neurotrofnih faktora;
control condition 3, when the charging power source is disconnected from the universal rechargeable battery, the lithium-ion battery charging/discharging control circuit detects the disconnection of the charging power source, and discharges remaining power stored in a filter capacitor during the charging, such that a voltage across a positive electrode and a negative electrode of the universal rechargeable battery drops rapidly to be equal to or lower than a maximum open circuit voltage and a discharging status is performed, and during the discharging status, the lithium-ion battery charging/discharging control circuit cutoffs a charging and performs a regulated voltage discharge, and performs a regulated voltage output according to control condition 4, wherein the maximum open circuit voltage ranges from 1.5V to 1.725V; 
kontrolni uvjet 3, kada je izvor punjenja isključen iz univerzalne punjive baterije, kontrolni krug za punjenje/pražnjenje litij-ionske baterije detektira isključenje izvora punjenja, i prazni preostalu snagu koja se nalazi u filter kondenzatoru tijekom punjenja, tako da napon na pozitivnoj elektrodi i negativnoj elektrodi univerzalne punjive baterije brzo pada kako bi bio jednak ili niži nego maksimalni napon otvorenog kruga i status pražnjenja je izvršen, a tijekom statusa pražnjenja, kontrolni krug za punjenje/pražnjenje litij-ionske baterije prekida punjenje i obavlja regulirano naponsko pražnjenje, i obavlja regulirani naponski izlaz prema kontrolnom uvjetu 4, gdje maksimalni napon otvorenog kruga je u opsegu od 1.5V do 1.725V;
control condition 7, during the discharging of the universal rechargeable battery, the lithium-ion battery charging/discharging control circuit detects the temperature of the lithium-ion battery, and cutoffs the regulated voltage output when the temperature of the lithium-ion battery raises to a discharging upper threshold temperature TDH and restores the regulated voltage output when the temperature of the lithium-ion battery decreases to be lower than TDH−ΔT2, wherein TDH is a preset discharging upper threshold temperature of the lithium-ion battery, and ΔT2 is a preset backlash temperature corresponding to a backlash voltage of the TDH detection threshold; 
kontrolni uvjet 7, tijekom pražnjenja univerzalne punjive baterije, kontrolni krug za punjenje/pražnjenje litij-ionske baterije detektira temperaturu litij-ionske baterije, i prekida regulirani naponski izlaz kada temperatura litij-ionske baterije raste do gornjeg praga temperature TDH pražnjenja i uspostavlja regulirani naponski izlaz kada se temperatura litij-ionske baterije smanji kako bi bila niža nego TDH-ΔT2, gdje TDH je unaprijed podešeni gornji prag temperature pražnjenja litij-ionske baterije, a ΔT2 je unaprijed podešena temperatura mrtve zone koja odgovara naponu mrtve zone TDH praga za detekciju;
identifying a lymphocyte of the mouse that expresses an antibody that specifically binds the antigen of interest, and obtaining a human immunoglobulin heavy chain variable region sequence that encodes a human immunoglobulin heavy chain variable domain of said antibody. 
identifikacije klonalno odabranog limfocita miša koji izražava antitijelo koje se specifično vezuje za interesni antigen te dobivanja iz limfocita ili antitijela nukleotidne sekvencije koja šifrira humanu varijabilnu regiju teškog lanca antitijela koje se specifično vezuje za interesni antigen.
The method of claim 1, wherein the zeta potential of the particle is from about −100 mV to about −40 mV. 
Spoj sukladno zahtjevu 1, pri čemu je zeta potencijal čestice od oko -50 mV do oko -40 mV.
The method of claim 1, wherein the particle has a diameter of about 0.5 μm. The method of claim 1, wherein said allergen is an environmental allergen or a food allergen. The method of claim 1, wherein said allergen comprises all or at least a portion of a protein selected from the group consisting of: ragweed pollen proteins, hair follicle antigen, human tropomyosin isoform 5, Bahia grass pollen (BaGP), peach allergen Pru p 3, alpha s 1-Caein Milk allergen, Apig1 celery allergen, Berel Brazil nut allergen, B-Lactoglobulin Milk allergen, Bovine serum albumin, Cor a 1.04 Hazelnut allergen, and Ovalbumin Egg allergen. 
Spoj sukladno zahtjevu 5, pri čemu spomenuti antigen sadrži, ili sadrži barem dio proteina odabranog iz skupine koja se sastoji od: mijelinskog bazičnog proteina, acetilkolinskog receptora, endogenog antigena, mijelinskog oligodendrocitnog glikoproteina, pankreasnog beta-staničnog antigena, inzulina, dekarboksilaze glutaminske kiseline (GAD), kolagena tipa 11, ljudskog hrskavičnog gp39, fp130-RAPS, proteolipidnog proteina, fibrilarina, malog nukleolarnog proteina, receptora za stimuliranje štitnjače, histona, glikoproteina gp70, dehidrolipoamid acetil transferaza (PCD-E2), antigen dlaka, A-gliaden, i humana tropomiozinska izoforma 5, pelud Bahia trave (BaGP), alergen breskve Pru p 3, alfa s 1-Caein mliječni alergen, Apig1 alergen celera, alergen Bere1 brazilskog oraha, B-laktoglobulin alergena mlijeka, serum alergena goveda, albumina Cor 1.04 lješnjaka, ili Ovalbumin alergena jaja.
A process for the preparation of a stable ophthalmic composition for topical administration for the treatment of ocular hypertension and glaucoma, comprising Brinzolamide or ophthalmologic acceptable salts thereof, as the active ingredient and from 0.01% to 0.05% by weight based on the total weight of the composition of surfactant poloxamer 407, in order to provide adequate solubilization and stabilization of the low soluble active ingredient in the aqueous formulations, wherein it comprises the following steps: 
Postupak za pripremu stabilnog oftalmološkog sastava za vanjsku primjenu za tretiranje okularne hipertenzije i glaukoma, sadržeći Brinzolamid ili oftalmološki prihvatljive soli istog, kao aktivan sastojak i od 0,01% do 0,05% težinskog udjela na temelju ukupne težine sastava površinski aktivnog poloksamera 407, kako bi se postiglo adekvatno rastapanje i stabilizacija aktivnog sastojka niske topljivosti u vodenastim formulacijama, naznačeno time da obuhvaća sljedeće korake:
First forming a solution of the surfactant in water for injection; 
Prvo formiranje otopine površinsko - aktivne tvari u vodi za injekciju;
Autoclaving the above mixture and subsequently homogenize until ambient temperature is reached; 
Sterilizacija smjese u autoklavu i naknadna homogenizacija dok se ne postigne temperatura okoline;
Passing the obtained solution through colloidal mill to reach the desired particle size; 
Propuštanje dobivene otopine kroz koloidalan mlin kako bi se postigla željena veličina čestica;
Subsequently, forming a second solution in water for injection by adding at least one osmotic agent, a tonicity agent, a suspending agent, a chelating agent and a preservative agent and mixing until complete homogeneity; 
Naknadno, formiranje druge otopine u vodi za injekciju dodavanje barem jednog osmotskog sredstva, sredstva za toničnost, sredstva za suspenziju, kelatnog sredstva i konzervansa i miješanje do potpune homogenosti;
adjusting the pH of the second solution by adding NaOH or HCl; 
Prilagodba pH vrijednosti druge otopine dodavanjem NaOH ili HCl;
autoclaving the obtained solution and subsequently homogenize until ambient temperature is reached; 
Sterilizacija smjese u autoklavu i naknadna homogenizacija dok se ne postigne temperatura okoline;
Mixing gradually the two formed solutions until uniform, and 
Postepeno miješanje dvaju formiranih otopina dok ne postanu homogene, i
Finally, adjusting the final mixture with water for injection and filling in appropriate container. 
Naposljetku, prilagodba konačne smjese s vodom za injekciju i punjenje u odgovarajuće spremnike.
The process according to claim 1, wherein the composition comprises also mannitol, benzalkonium chloride, edetate disodium, sodium chloride and carbomer. 
Postupak u skladu sa zahtjevom 1, naznačen time da sastav sadrži i manitol, benzalkonijev klorid, dinatrijev edetat, natrijev klorid i karbomer.